Management of hypokalemia and hyperkalemia (pharmacology)

Reading File

Finding Sources

Reading File

Loading Image

I now have comprehensive, detailed pharmacological content from multiple authoritative sources. Let me compile the full answer.

Management of Hypokalemia and Hyperkalemia - Pharmacology

HYPOKALEMIA

Definition & Severity Classification

Severity	Serum K⁺
Mild	3.0 - 3.5 mEq/L
Moderate	2.5 - 3.0 mEq/L
Severe	< 2.5 mEq/L

Hypokalemia is the most common electrolyte abnormality in clinical practice - affecting >20% of hospitalized patients and up to 40% of outpatients on thiazide diuretics.

Key rule: Each 0.3 mEq/L drop in serum K⁺ below normal corresponds to roughly 100 mEq of total body potassium deficit.

ECG Changes in Hypokalemia

Progressive changes with falling K⁺:

T-wave flattening
Prominent U wave (deflection after T wave)
ST-segment depression
Prolonged QT interval (>500 ms raises risk of torsades de pointes 2-3x)
Increased P-wave amplitude, prolonged PR interval

Pharmacological Management of Hypokalemia

Treatment depends on severity and presence of organ dysfunction (especially cardiac).

1. Oral Potassium Replacement (Mild-to-Moderate Hypokalemia)

Drug of choice: Potassium chloride (KCl) - preferred because co-existing hypochloremic alkalosis benefits from chloride as well
Available in liquid, powder, and tablet form
Dose: 40-60 mEq PO every 2-4 hours, well tolerated
Maintenance/chronic: 60-80 mEq/day
Suitable when no nausea/vomiting is driving the hypokalemia

2. Intravenous Potassium Replacement (Severe or Symptomatic Hypokalemia)

Reserved for: significant ECG changes, arrhythmias, severe muscle weakness, K⁺ < 2.0 mEq/L, or QT > 500 ms
Goal of IV therapy: Remove from immediate danger - not to correct entire deficit
Standard rate: 10-20 mEq/hr via peripheral line
Rates > 20 mEq/hr: require central venous access + continuous cardiac monitoring
Peripheral IV should not exceed 8 mEq/hr due to venous irritation
Maximum daily dose: 240 mEq/day
Avoid dextrose-containing solutions - they stimulate insulin release, which drives K⁺ into cells and can worsen hypokalemia transiently

3. Treat Concurrent Hypomagnesemia

Hypokalemia is very frequently associated with hypomagnesemia
Magnesium deficiency impairs renal K⁺ conservation - potassium replacement fails until Mg²⁺ is corrected
Always check and replete magnesium when treating hypokalemia; suspect hypomagnesemia if K⁺ does not respond to replacement

4. Potassium-Sparing Strategies (Prevention/Chronic Management)

For diuretic-induced hypokalemia, the mechanism involves 4 pathways: increased tubular flow, AVP secretion, aldosterone secretion, and metabolic alkalosis. Drugs used to prevent or treat:

Drug Class	Agents	Mechanism
Mineralocorticoid receptor antagonists	Spironolactone, eplerenone	Block aldosterone-driven K⁺ secretion
ENaC blockers	Amiloride, triamterene	Block sodium reabsorption in collecting duct, reduce K⁺ secretion
ACE inhibitors / ARBs	Enalapril, losartan	Suppress RAAS, reduce aldosterone
Direct renin inhibitors	Aliskiren	Suppress RAAS upstream

Special Considerations

Digoxin toxicity: Hypokalemia sensitizes the heart to digoxin toxicity - aggressive K⁺ repletion is critical in this setting
Cardiac patients (heart failure, MI, arrhythmia): Target K⁺ 4.0-5.0 mEq/L; even mild hypokalemia is an independent risk factor for morbidity/mortality
Beta-agonists as a cause: Albuterol 1 standard nebulized dose reduces K⁺ by 0.2-0.4 mEq/L; a second dose within 1 hour can reduce it by ~1 mEq/L

HYPERKALEMIA

Definition & Severity Classification

Severity	Serum K⁺
Mild	5.5 - 6.0 mEq/L
Moderate	6.1 - 6.9 mEq/L
Severe	≥ 7.0 mEq/L

K⁺ > 6 mEq/L should always be corrected due to lethal potential.

ECG Changes in Hyperkalemia

Sequential progression with rising K⁺:

Peaked (tented) T waves - usually at K⁺ > 5.5-6.5 mEq/L
Widening QRS complex
PR prolongation → P wave disappearance (at K⁺ > 6.5-7.5 mEq/L)
Loss of R-wave amplitude, ST changes
Sine wave pattern → Ventricular fibrillation / asystole (at K⁺ > 7-8 mEq/L)

The 3-Step Framework for Hyperkalemia Treatment

Treatment is organized into three sequential goals:

Step 1: Stabilize the cardiac membrane Step 2: Shift K⁺ into cells (temporizing) Step 3: Remove K⁺ from the body (definitive)

Step 1 - Cardiac Membrane Stabilization

Drug	Dose	Onset	Duration	Notes
Calcium gluconate 10%	10 mL (1 g) IV over 2-3 min; repeat after 5 min if needed	1-3 min	30-60 min	First-line for ECG changes
Calcium chloride 10%	5-10 mL (0.5-1 g) IV	1-3 min	30-60 min	More elemental Ca²⁺ per mL (3x), can cause tissue necrosis if extravasated - prefer central line

Mechanism: Calcium raises the cardiac action potential threshold, directly antagonizing the depolarizing effect of hyperkalemia on myocardial cell membranes. Does NOT lower serum K⁺.
Caution with digoxin: Calcium potentiates digoxin toxicity - give slowly and with caution in digoxin patients

Step 2 - Shifting K⁺ into Cells (Temporizing)

These agents lower serum K⁺ quickly but do not remove it from the body.

Drug	Dose	Onset	Peak Effect	K⁺ Reduction
Regular insulin + Dextrose	Insulin 10 units IV push + Dextrose 50% 50 mL (25 g) IV push	< 15 min	30-60 min	~0.6 mEq/L
Nebulized albuterol	10-15 mg by continuous inhalation (high dose)	< 15 min	30-60 min	0.5-1.0 mEq/L
Sodium bicarbonate	50-100 mEq IV infusion	~15 min	Variable	Modest
Beta-2 agonists (IV/SC)	Low-dose epinephrine infusion	Minutes	Rapid	Useful in massive transfusion

Notes on each agent:

Insulin + Glucose: Activates Na⁺/K⁺-ATPase, driving K⁺ intracellularly. Use 5 units insulin if renal dysfunction (to avoid hypoglycemia). Monitor glucose closely. Dextrose is withheld if patient is already hyperglycemic (serum glucose > ~250 mg/dL).
Albuterol: Beta-2 stimulation activates Na⁺/K⁺-ATPase. Additive with insulin - combined effect is greater. Particularly useful as an adjunct. Do NOT use as monotherapy in severe hyperkalemia.
Sodium bicarbonate: Corrects acidosis, which drives H⁺ out of cells and K⁺ back in. Most effective when metabolic acidosis is present. Less effective in isolated hyperkalemia without acidosis. Also provides sodium load (beneficial in some scenarios).
Normal saline bolus (100-250 mL): Used in conjunction with nephrologist guidance if patient is dialysis-dependent.

Step 3 - Remove K⁺ from the Body (Definitive)

Method	Onset	Notes
Hemodialysis	Immediate/reliable	Reduces K⁺ by ~1 mEq/L in first hour, another 1 mEq/L over next 2 hours. Definitive treatment. Required in renal failure.
Furosemide (loop diuretic) + IV fluids	Minutes to hours	Effective with intact renal function (e.g., rhabdomyolysis, tumor lysis). Administer by slow infusion (not bolus) to reduce ototoxicity risk. Not reliable in acute management.
Sodium polystyrene sulfonate (SPS, Kayexalate)	4-6+ hours	NOT effective for acute/urgent management. Onset too slow. FDA black box warning: risk of intestinal necrosis, especially with abnormal bowel function.
Patiromer (Veltassa)	Hours (chronic use)	Non-absorbed cation exchange polymer - binds K⁺ in exchange for Ca²⁺ in GI tract. FDA-approved for chronic hyperkalemia. Not for acute/urgent use.
Sodium zirconium cyclosilicate (Lokelma)	Hours	Highly selective cation exchanger - traps K⁺ in intestines in exchange for Na⁺ and H⁺. Useful for chronic hyperkalemia in CKD and heart failure.

Specific Drug Causes of Hyperkalemia to Address

When drugs are the cause, discontinuation is the primary step:

ACE inhibitors / ARBs
NSAIDs
Spironolactone, amiloride, triamterene
Succinylcholine (especially dangerous in CKD patients already hyperkalemic - rapid K⁺ release from depolarizing blockade)
Beta-blockers (impair K⁺ uptake into cells)
Digoxin overdose
Potassium supplements

For hypoaldosteronism-driven hyperkalemia: mineralocorticoid replacement (fludrocortisone) is the targeted treatment.

Anesthetic Considerations in Hyperkalemia

Elective surgery should be postponed in significant hyperkalemia
Succinylcholine is absolutely contraindicated - causes K⁺ release from muscle depolarization
Avoid potassium-containing IV fluids (e.g., Lactated Ringer's)
Prevent acidosis (both metabolic and respiratory) - acidosis drives K⁺ extracellularly
Consider mild hyperventilation under general anesthesia
Monitor neuromuscular blockade closely - hyperkalemia potentiates non-depolarizing NMBs

Summary Table: Hypokalemia vs. Hyperkalemia Pharmacology

Feature	Hypokalemia	Hyperkalemia
ECG	T-wave flat, U wave, ↑QT	Peaked T, wide QRS, P loss, sine wave
Cardiac danger	Arrhythmias, digoxin toxicity	VF/asystole, cardiac arrest
Acute drug Rx	KCl IV 10-20 mEq/hr	Calcium gluconate → Insulin/glucose → Albuterol
Oral Rx	KCl 40-60 mEq q2-4h	Patiromer, SPS (chronic only)
Associated deficiency to correct	Magnesium	N/A
Definitive removal	N/A	Hemodialysis (renal failure), furosemide (intact kidneys)
Avoid	Dextrose-only IVF, insulin without glucose	Succinylcholine, K⁺-containing IVF, ACEi/ARBs

Sources:

Rosen's Emergency Medicine, 9e - Chapter 114
Morgan & Mikhail's Clinical Anesthesiology, 7e - Chapter 49
Current Surgical Therapy, 14e
Brenner and Rector's The Kidney, 2-Volume Set - Chapter 50

from kd tripathi

Finding Sources

Unfortunately, KD Tripathi's Essentials of Medical Pharmacology is not available in the medical textbook library. The pharmacology books currently in the library are:

Goodman & Gilman's The Pharmacological Basis of Therapeutics
Katzung's Basic and Clinical Pharmacology, 16th Edition
Lippincott Illustrated Reviews: Pharmacology
Stahl's Essential Psychopharmacology

I can cover the hypokalemia and hyperkalemia management from any of these - especially Goodman & Gilman's or Katzung's, which are the most comprehensive pharmacology references available. Alternatively, I can present the topic in the style and format typical of KD Tripathi (concise, classification-based, tabular, exam-oriented) using pharmacological principles from the available texts.

Which would you prefer?

From Goodman & Gilman's (closest authoritative pharmacology reference in the library)
From Katzung's Basic & Clinical Pharmacology
In KD Tripathi style (concise, tabular, classification-focused) synthesized from available sources

Management of hypokalemia and hyperkalemia kd tripathi

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have enough solid pharmacological content. I'll now compile everything in KD Tripathi's characteristic style - concise, classification-based, bold drug names, mechanism-dose-side effect format, with a clean layout.

Management of Hypokalemia and Hyperkalemia

(In the style of KD Tripathi's Essentials of Medical Pharmacology)

Note: KD Tripathi's textbook is not available in this library. This response is presented in KD Tripathi's characteristic writing style - concise, tabular, drug-classification-based, with mechanism, dose, and notes - drawing from Katzung's Basic & Clinical Pharmacology (16e), Rosen's Emergency Medicine (9e), Barash's Clinical Anesthesia (9e), and Morgan & Mikhail's Clinical Anesthesiology (7e).

HYPOKALEMIA

Normal serum K⁺: 3.5-5.0 mEq/L Hypokalemia: serum K⁺ < 3.5 mEq/L

Severity	K⁺ level
Mild	3.0 - 3.5 mEq/L
Moderate	2.5 - 3.0 mEq/L
Severe	< 2.5 mEq/L

Rule of thumb: Each 0.3 mEq/L fall below normal ≈ 100 mEq total body K⁺ deficit

ECG Changes in Hypokalemia

ECG progression in hypokalemia - T-wave flattening, prominent U wave at K⁺ 3.9, 2.7, 1.3 mEq/L

Flattening of T wave → prominent U wave (after T wave)
ST-segment depression
Prolonged QT interval → risk of torsades de pointes (if QT > 500 ms)
Increased P-wave amplitude, PR prolongation

Treatment of Hypokalemia

Treatment depends on severity and presence of organ dysfunction.

A. ORAL POTASSIUM REPLACEMENT

(For mild to moderate hypokalemia, asymptomatic)

Potassium Chloride (KCl) — Drug of choice

Why KCl? Most hypokalemia is accompanied by metabolic alkalosis and hypochloremia; chloride co-repletion corrects both.
Dose: 40-60 mEq orally every 2-4 hours; maintenance 60-80 mEq/day
Forms: Liquid, powder (sachets), slow-release tablets (Slow-K)
SE: GI irritation, nausea, GI ulceration with slow-release forms
Avoid: Enteric-coated tablets (erratic absorption, GI ulcers)

Alternatives:

Potassium bicarbonate/citrate - preferred if acidosis is also present
Dietary sources - bananas, oranges, tomatoes (insufficient alone in deficiency)

B. INTRAVENOUS POTASSIUM REPLACEMENT

(For severe hypokalemia, significant ECG changes, arrhythmias, weakness)

Drug: Potassium Chloride (KCl) IV infusion

Route	Max Rate	Condition
Peripheral IV	10 mEq/hr (max 20 mEq/hr)	Standard
Peripheral IV	Do NOT exceed 8 mEq/hr	Avoids vein irritation
Central venous	10-20 mEq/hr	Rapid replacement with ECG monitoring
Any route	> 20 mEq/hr	Only for K⁺ < 2.0 mEq/L or QT > 500 ms; mandatory cardiac monitoring

Max daily dose: 240 mEq/day
Goal: Remove from immediate danger - NOT correct entire deficit in one go
Important: Use normal saline as diluent - NOT dextrose. Dextrose stimulates insulin → drives K⁺ into cells → transiently worsens hypokalemia
Digoxin patients: Hypokalemia potentiates digoxin toxicity. Aggressive K⁺ repletion is mandatory; target K⁺ 4.0-5.0 mEq/L

C. TREAT CONCURRENT HYPOMAGNESEMIA

Hypokalemia frequently co-exists with hypomagnesemia
Mg²⁺ deficiency impairs renal K⁺ conservation - K⁺ replacement will fail unless Mg²⁺ is corrected first
Magnesium sulfate (MgSO₄) IV given concurrently

D. DRUGS USED TO PREVENT/TREAT DIURETIC-INDUCED HYPOKALEMIA

(Potassium-sparing agents)

Drug	Class	Mechanism	Dose
Spironolactone	Aldosterone antagonist	Blocks mineralocorticoid receptor → reduces K⁺ secretion in collecting duct	25-100 mg/day
Eplerenone	Selective aldosterone antagonist	Same as spironolactone; fewer hormonal SE	25-50 mg/day
Amiloride	ENaC blocker	Blocks Na⁺ channel in collecting duct → reduces electrochemical gradient for K⁺ secretion	5-10 mg/day
Triamterene	ENaC blocker	Same as amiloride	50-150 mg/day

Also used (RAAS inhibitors that reduce aldosterone):

ACE inhibitors (enalapril, ramipril)
ARBs (losartan, valsartan)
Direct renin inhibitor (aliskiren)

Note from Katzung: Loop diuretics increase K⁺ secretion by 4 mechanisms - ↑tubular flow, ↑AVP, ↑aldosterone, metabolic alkalosis. K⁺-sparing agents counteract these. At least one study showed K⁺ supplementation at initiation of loop diuretics (regardless of serum K⁺) improves survival.

HYPERKALEMIA

Hyperkalemia: serum K⁺ > 5.0 mEq/L

Severity	K⁺ level
Mild	5.5 - 6.0 mEq/L
Moderate	6.1 - 6.9 mEq/L
Severe	≥ 7.0 mEq/L

K⁺ > 6 mEq/L must always be treated due to risk of fatal arrhythmia.

ECG Changes in Hyperkalemia (Sequential)

ECG progression in hyperkalemia - peaked T waves, widening QRS, sine wave pattern

Peaked (tented) T waves - first sign (K⁺ ~5.5-6.5 mEq/L)
Widened QRS
PR prolongation → P wave disappears (K⁺ ~6.5-7.5 mEq/L)
Sine wave pattern (K⁺ > 7-8 mEq/L)
VF / Asystole → death

Hypocalcemia, hyponatremia, and acidosis accentuate the cardiac toxicity of hyperkalemia.

Treatment of Hyperkalemia — The 3-Step Approach

STEP 1 → Stabilize cardiac membrane  (fastest, buys time)
STEP 2 → Shift K⁺ into cells         (temporizing, ~60 min)
STEP 3 → Remove K⁺ from body         (definitive)

STEP 1 — Cardiac Membrane Stabilization

Calcium Salts — antagonize the membrane effects of hyperkalemia directly

Drug	Dose	Onset	Duration
Calcium gluconate 10%	10 mL (1 g) IV over 2-3 min; repeat after 5 min if no response	1-3 min	30-60 min
Calcium chloride 10%	5-10 mL IV	1-3 min	30-60 min

Mechanism: Raises the threshold potential of cardiac myocytes → antagonizes the depolarizing effect of high extracellular K⁺ on the resting membrane potential. Does NOT lower serum K⁺.
CaCl₂ vs gluconate: CaCl₂ provides ~3x more elemental calcium per mL but causes tissue necrosis if extravasated → prefer central line; gluconate is safer peripherally
Caution: In digoxin toxicity - calcium potentiates digoxin cardiac toxicity; administer slowly and monitor ECG

STEP 2 — Shift K⁺ into Cells (Temporizing)

All agents here lower serum K⁺ within 15-60 min but do not remove K⁺ from body.

1. Insulin + Glucose (Most reliable, first-line)

Parameter	Detail
Drug	Regular insulin + 50% Dextrose
Dose	Insulin 10 units IV bolus + Dextrose 50 mL (25 g) IV
In renal failure	Insulin 5 units (to reduce hypoglycemia risk)
In hyperglycemia	Insulin without dextrose if glucose > ~250 mg/dL
Onset	< 15 minutes
Duration	30-60 minutes
K⁺ reduction	~0.6 mEq/L
Mechanism	Activates Na⁺/K⁺-ATPase → drives K⁺ intracellularly
Monitor	Blood glucose (hypoglycemia risk)

2. Beta-2 Agonists

Parameter	Detail
Drug	Salbutamol (Albuterol) nebulized
Dose	10-15 mg by continuous nebulization (high dose)
Onset	< 15 minutes
K⁺ reduction	0.5-1.0 mEq/L
Mechanism	Stimulates β₂ receptors → activates Na⁺/K⁺-ATPase → intracellular K⁺ shift
Note	Additive with insulin - combined effect > either alone
Caution	Do NOT use as monotherapy in severe hyperkalemia. Tachycardia as SE.

For massive transfusion-related hyperkalemia: low-dose IV epinephrine infusion - rapid K⁺ shift + inotropic support.

3. Sodium Bicarbonate

Parameter	Detail
Dose	50-100 mEq IV over 5-10 min
Onset	~15 minutes
Mechanism	Corrects acidosis → H⁺ exits cells in exchange for K⁺ (K⁺ shifts intracellularly)
Best used	Only when metabolic acidosis is concurrently present
Least effective	Hyperkalemia without acidosis

STEP 3 — Remove K⁺ from Body (Definitive)

1. Hemodialysis (Most effective)

Reduces K⁺ by ~1 mEq/L in first hour, another ~1 mEq/L over next 2 hours
Indication: Renal failure (oliguric AKI, CKD, CRF), life-threatening hyperkalemia, failed medical management
Only reliable definitive method in renal failure

2. Loop Diuretics (Intact renal function only)

Drug: Furosemide IV
Enhances urinary K⁺ excretion; supplement with NaCl + water infusion to maintain euvolemia
Administer by slow IV infusion (not bolus) to reduce ototoxicity risk
Useful in rhabdomyolysis, tumour lysis syndrome (intact urine output)

3. Cation Exchange Resins

Drug	Mechanism	Onset	Use
Sodium polystyrene sulfonate (SPS, Kayexalate)	Exchanges Na⁺ for K⁺ in gut	4-6 hours	NOT for acute/emergency management. Risk of intestinal necrosis (FDA black box warning). Oral or rectal.
Patiromer (Veltassa)	Non-absorbed polymer; binds K⁺ in exchange for Ca²⁺ in GI tract	Hours	Chronic hyperkalemia (CKD, heart failure). FDA-approved. NOT for acute use.
Sodium Zirconium Cyclosilicate (SZC, Lokelma)	Highly selective cation exchanger; traps K⁺ in intestine in exchange for Na⁺/H⁺	~4 hours (K⁺ < 5.5 mEq/L in median 4 hrs in trials)	Chronic hyperkalemia. Approved in US and EU. NOT for acute/emergency use.

SPS is no longer recommended for emergent management due to lack of efficacy within 4 hours and serious GI complications. Patiromer and SZC are preferred for outpatient chronic hyperkalemia management.

Drugs That CAUSE Hyperkalemia (to identify and stop)

Drug/Class	Mechanism
ACE inhibitors, ARBs	↓ angiotensin II → ↓ aldosterone → ↓ K⁺ excretion
Spironolactone, amiloride, triamterene	Direct K⁺-sparing action
NSAIDs	↓ renin → ↓ aldosterone (type IV RTA pattern)
Beta-blockers	Impair K⁺ uptake into cells
Succinylcholine	Depolarization → K⁺ efflux from muscle; absolutely contraindicated in hyperkalemia
Heparin	↓ adrenal aldosterone synthesis
Digoxin overdose	Inhibits Na⁺/K⁺-ATPase → K⁺ leaks out of cells

For hypoaldosteronism-induced hyperkalemia → Fludrocortisone (mineralocorticoid replacement)

Quick Comparison Table

Feature	Hypokalemia	Hyperkalemia
K⁺ level	< 3.5 mEq/L	> 5.0 mEq/L
ECG hallmark	Flat T, prominent U wave, ↑QT	Peaked T waves → sine wave
First-line acute drug	KCl oral/IV	Calcium gluconate IV
Temporizing (shift K⁺)	N/A	Insulin + glucose, Albuterol
Definitive removal	N/A	Dialysis (renal failure), Furosemide (intact kidneys)
Chronic oral drug	KCl + K⁺-sparing diuretic	Patiromer / SZC
Avoid	Dextrose IVF alone, delay in Mg²⁺ correction	Succinylcholine, K⁺-containing IVF, SPS in acute setting
Key associated deficiency	Hypomagnesemia	N/A
Digoxin interaction	Potentiates toxicity (replace K⁺ aggressively)	Calcium potentiates digoxin toxicity (give cautiously)

Sources: Katzung's Basic & Clinical Pharmacology 16e, Rosen's Emergency Medicine 9e, Morgan & Mikhail's Clinical Anesthesiology 7e, Barash's Clinical Anesthesia 9e

Create a concise PDF reference card for hypokalemia and hyperkalemia management

Reading File

Running Command

Writing File

Running Command

Your reference card is ready. Here's what's included across the single A4 page:

Sections covered:

Classification - Severity grades for both hypokalemia and hyperkalemia side-by-side
ECG Changes - Sequential changes for both disorders in a parallel table
Hypokalemia Treatment - KCl oral and IV dosing table with routes, rates, and cautions
K⁺-Sparing Drugs - Spironolactone, eplerenone, amiloride, triamterene, ACEi/ARBs with mechanisms and doses
Hyperkalemia 3-Step Table - Step 1 (Ca gluconate/chloride), Step 2 (insulin+glucose, albuterol, bicarb), Step 3 (furosemide, patiromer, SZC, dialysis) with onset and K⁺ reduction per agent
Drugs Causing Hyperkalemia - With mechanisms
Quick Comparison Summary - Side-by-side at-a-glance table

Colour coding: Blue = hypokalemia, Red = hyperkalemia, Amber = warnings, Green = key pearls

Potassium Management Refcard

PDF Document · PDF

This is a shared conversation. Sign in to Orris to start your own chat.